ERBB2 and breast carcinoma: The aim of this work was to evaluate whether the effect of neoadjuvant pertuzumab combined with trastuzumab in comparison with trastuzumab alone varies as a function of PAM50-defined intrinsic subtypes in a real-world cohort of patients with HER2-positive early breast cancer.